Trial Profile
Response measurement study in metastatic castration-resistant prostate cancer patients, treated with radium-223, to improve early response evaluation and understand the radium-223 induced immune response
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms Radium223Insight
- 18 Nov 2018 New trial record